Abivax's $650M Public Offering of ADS

Paris-based Abivax, a clinical-stage biotech firm, announced the pricing of its $650 million public offering. The offering involves 10,156,000 American Depositary Shares (ADSs), each priced at $64.00, equating to €54.58 per share. This offering is conducted without shareholders' preferential subscription rights. The planned closure is on July 28, 2025, subject to meeting customary closing conditions.

The offering may result in an estimated $650 million in gross proceeds, with potential additional gains if underwriters exercise their option fully. Proceeds will fund clinical developments for drugs targeting ulcerative colitis and Crohn’s disease, further working capital, and corporate obligations. Dilution impacts approximately 16% of company share capital.

Abivax's existing cash plus anticipated net proceeds should support operations until Q4 2027. The company's financial use strategy remains flexible, contingent on trial progress and market conditions.